Research ArticleResearchWorkflowPatient Education

Digital symptom monitoring with nurse follow-up preserved quality of life and reduced inpatient days in advanced cancer

JAMA Network Open (PubMed)Jun 1, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a six-clinic randomized trial of 1,214 adults with advanced solid cancer, weekly app-based symptom monitoring with automated guidance and nurse follow-up better maintained quality of life and self-efficacy; fewer participants had worsening unplanned-hospitalization episodes, and inpatient days were lower than with usual care over 18 weeks.

What NurseJet pulled from the source

This multicenter randomized trial enrolled 1,214 community-dwelling adults with advanced solid cancer at six palliative care clinics in Hong Kong. Participants were no longer receiving systemic anticancer treatment and received either usual care or weekly app symptom reporting, automated self-management guidance, and nurse follow-up for severe symptom alerts. At 18 weeks, health-related quality of life and self-efficacy were better maintained with digital monitoring. Among participants included in the hospitalization analysis, fewer had worsening unplanned hospitalization episodes (17.2% versus 28.5%), and mean inpatient days were 3.4 versus 7.3. Emergency-department use and deterioration in performance status did not differ significantly. The findings support the combined monitoring-and-response pathway studied, rather than an app acting alone.

Why this matters for nurses

Oncology and palliative-care nurses often coordinate symptom surveillance between visits and decide which reports need timely follow-up. This trial matters because it tested a defined response pathway in a large randomized sample and separated improvements in quality of life and hospitalization from outcomes that did not significantly change.

Bedside takeaway

Worth knowing that weekly digital symptom reporting paired with nurse follow-up better maintained quality of life and reduced inpatient days in a 1,214-person advanced-cancer trial.

How This Applies in Practice

Use this when: Evaluating a structured remote symptom-monitoring pathway for community-dwelling adults with advanced solid cancer who are no longer receiving systemic therapy.

On your shift

Include a defined response workflow so severe app-reported symptoms trigger nurse follow-up rather than relying on passive monitoring alone.
Track quality of life, self-efficacy, unplanned hospitalizations, and inpatient days when evaluating the pathway.

Keep in mind: The trial combined weekly reporting, automated guidance, and nurse follow-up at six Hong Kong palliative clinics. Follow facility policy and do not generalize the results to patients receiving active systemic therapy without further evidence.

Explain this for my unit

Key takeaways

The six-clinic trial randomized 1,214 adults with advanced solid cancer to digital symptom monitoring plus usual care or usual care alone.
The intervention combined weekly symptom reports, automated self-management guidance, and nurse follow-up for severe alerts.
Quality of life and self-efficacy were better maintained over 18 weeks with digital monitoring.
Fewer analyzed participants had worsening unplanned hospitalization episodes, and mean inpatient days were lower, while emergency-department use was not significantly different.

Practice implications

For oncology services considering remote monitoring, the intervention should be understood as weekly reporting plus automated guidance plus a staffed nurse-response workflow. The results do not show that passive symptom collection alone is effective, and they should not be generalized beyond the studied advanced-cancer population without local evaluation.

Limitations & cautions

The trial was conducted in six Hong Kong palliative clinics among community-dwelling adults with advanced solid cancer who were no longer receiving systemic therapy. Follow-up was 18 weeks, caregivers used the app for many participants, and hospitalization and performance-status results in the abstract were reported for smaller analyzed groups than the 1,214 people randomized.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

JAMA Network Open (PubMed)

JAMA Network Open (PubMed). Digital Self-Management of Symptoms and Quality of Life for Patients With Advanced Cancer: A Randomized Clinical Trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42224222/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

European Journal of Oncology Nursing (PubMed)Jul 2, 2026Research Article

In a 12-week pilot randomized trial in Vietnam, a nurse-led nutritional self-management program left significantly more chemotherapy patients free of diarrhea and constipation at 3 to 4 weeks than usual care, and it proved highly feasible and acceptable.

OncologyAI summaryReview source

Research ArticleResearchPatient EducationAI summary · original source linked below

This pilot randomized study tested a co-designed, nurse-led nutritional support program for chemotherapy-induced diarrhea (CID) and constipation (CIC) among adult cancer patients in Vietnam. The 12-week intervention combined face-to-face education, a culturally tailored booklet, personalized dietary support, promotion of self-management strategies, and weekly telephone follow-up. Feasibility was strong, with a 94.1% recruitment rate and 98.8% completion, and acceptability was high, with all participants attending education sessions, 95% completing telephone support, and over 80% adopting the recommended self-management strategies. At weeks 3 to 4, the intervention group had a significantly higher proportion of patients free from both CID and CIC (53.8% vs 27.5%, p=0.01) and free from constipation alone (74.4% vs 45%, p=0.01), with improvements sustained at week 12 in a sub-sample of intervention participants.

Key takeaways

At 3 to 4 weeks, more intervention patients were free of both diarrhea and constipation than usual-care patients (53.8% vs 27.5%, p=0.01).
Freedom from constipation alone was also higher in the intervention group (74.4% vs 45%, p=0.01).
The program was highly feasible (94.1% recruitment, 98.8% completion) and acceptable (over 80% adopted self-management strategies).
Gains were sustained at 12 weeks within a sub-sample, and the authors call for a fully powered randomized controlled trial.

Why this matters on shift

Diarrhea and constipation are common, distressing chemotherapy side effects that can erode nutrition and force treatment changes, yet non-drug options are under-studied. This study may matter for nurses because it tests a low-cost, nurse-led package of education, diet support, and phone follow-up that patients readily took up and that eased these symptoms early on.

Bedside takeaway

Worth knowing that in a small pilot trial, a nurse-led nutrition support program left more chemotherapy patients free of diarrhea and constipation at 3 to 4 weeks (about 54% vs 28%) than usual care.

Nursing implications

For oncology nurses, the findings suggest that a structured, nurse-led program of dietary education, self-management coaching, and regular telephone follow-up can help chemotherapy patients manage diarrhea and constipation and is well accepted by patients. Because this was a small pilot, any such program should be pursued through the treating team rather than adopted as established practice.

Limitations & cautions

This was a single-country pilot randomized trial designed to test feasibility rather than to prove effectiveness, so the sample was small and the 12-week outcomes came from a sub-sample of intervention participants only. The culturally tailored, low-resource design may not transfer directly to other settings, and the authors state that a fully powered randomized controlled trial is still needed.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

European Journal of Oncology Nursing (PubMed). A nurse-led self-management nutritional support intervention for chemotherapy-induced diarrhea and constipation in patients with cancer: A pilot study.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Oncology Research and Treatment (PubMed)Jun 22, 2026Research Article

In a single-center prospective study of 72 head and neck cancer patients receiving concurrent chemoradiotherapy, adding honey and cryotherapy to routine care delayed the onset of radiation-induced oral mucositis and lowered the incidence of moderate-to-severe cases compared with routine nursing care alone.

OncologyAI summaryReview source

Research ArticleResearchAI summary · original source linked below

This single-center prospective comparative study enrolled 72 head and neck cancer patients receiving concurrent chemoradiotherapy at a specialized oncology institution between July 2021 and May 2022, allocating 36 to honey plus cryotherapy and 36 to routine nursing care. The intervention was applied before radiotherapy, 15 minutes after, and 6 hours afterward, with radiation-induced oral mucositis (RTOM) graded by Radiation Therapy Oncology Group (RTOG) criteria. The intervention group had a later onset of RTOM (15.58 ± 4.60 days vs 11.58 ± 6.22 days; P = 0.003) and a lower incidence of grade II or higher RTOM (11.11% vs 33.33%; P = 0.045). Severity grading also differed significantly in the second week (P = 0.005) and third week (P = 0.014) of treatment.

Key takeaways

Honey combined with cryotherapy delayed the onset of radiation-induced oral mucositis (15.58 vs 11.58 days; P = 0.003).
The incidence of grade II or higher mucositis was lower with the intervention (11.11% vs 33.33%; P = 0.045).
Severity grading favored the intervention group in both the second week (P = 0.005) and third week (P = 0.014) of treatment.
The study was small (72 patients, 36 per group) and single-center, and the authors call for further validation.

Why this matters on shift

Radiation-induced oral mucositis is one of the most painful and treatment-limiting complications of head and neck chemoradiotherapy, and it can force breaks in therapy. This study may matter for nurses because it tests a simple, low-cost bedside intervention, honey plus ice, that patients can tolerate and that nursing staff can deliver.

Bedside takeaway

Be aware that in a small single-center study, adding honey and cryotherapy around radiotherapy delayed radiation mouth sores (about 15.6 vs 11.6 days to onset) and cut grade II or higher mucositis from 33% to 11%.

Nursing implications

For oncology nurses caring for head and neck cancer patients on chemoradiotherapy, the findings suggest that a structured honey and cryotherapy routine around radiotherapy sessions may postpone and soften oral mucositis, improving comfort and treatment tolerance. Any such protocol should be adopted through the treating team rather than improvised, given the small single-center evidence base.

Limitations & cautions

This was a single-center prospective study of only 72 patients conducted between July 2021 and May 2022, so the results may not generalize and could reflect local practice. The authors describe the benefit as probable and explicitly call for more comprehensive studies before honey plus cryotherapy is treated as established practice.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Oncology Research and Treatment (PubMed). Efficacy of Honey Combined with Cryotherapy in the Prevention and Management of Radiation-Induced Oral Mucositis in Patients Undergoing Concurrent Chemoradiotherapy for Head and Neck Cancer.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Clinical Journal of Oncology Nursing (PubMed)Sep 17, 2025Clinical Guideline

A new joint ONS/ASCO guideline standardizes how to manage chemotherapy extravasation, covering antidotes, thermal compresses, and when to refer for surgery.

OncologyAI summaryReview source

Clinical GuidelineGuidelineMedication SafetyAI summary · original source linked below

The Oncology Nursing Society and ASCO convened a panel that used GRADE methodology and a systematic review to build an evidence-based guideline on managing antineoplastic extravasation, the leak of a tissue-damaging drug into surrounding tissue. The recommendations cluster around three decisions: antidote use for vesicants and irritants with vesicant properties, thermal compress application and duration, and early surgical referral or specialty escalation, specifically for extravasation involving a central venous access device.

Key takeaways

ONS and ASCO jointly published a guideline on managing antineoplastic extravasation, built with GRADE methodology and a systematic review.
Recommendations address antidote use for vesicants and for irritants with vesicant properties.
They also address thermal compress application and how long to apply it.
They call for early surgical referral or specialty escalation for extravasation involving a central venous access device.

Why this matters on shift

Extravasation is rare, so the muscle memory for responding often isn't there when it happens at the chair. A current, jointly endorsed guideline may matter because it gives a defensible framework for the first minutes after a suspected leak, the period that most shapes tissue outcome, and it flags central-line extravasation as a scenario that may warrant early escalation rather than watchful waiting.

Bedside takeaway

Worth knowing that a new joint ONS/ASCO guideline standardizes chemotherapy extravasation response, covering antidote use, thermal compresses, and early escalation when a central line is involved.

Nursing implications

Know where your unit's extravasation protocol and antidote kit live before a leak happens, and confirm they reflect current ONS/ASCO guidance. Determine whether a leaked agent is a vesicant or an irritant with vesicant properties, apply the correct thermal compress for the recommended duration, and escalate a central venous access device extravasation early rather than waiting.

Limitations & cautions

As a consensus practice guideline, the strength of individual recommendations depends on evidence that is often limited for a rare event. The abstract names recommendation topics but not specific agents, temperatures, or durations, so the full text must be read before applying any intervention.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Clinical Journal of Oncology Nursing (PubMed). ONS/ASCO Guideline on the Management of Antineoplastic Extravasation.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

A nurse-led nutrition program left more chemo patients free of diarrhea and constipation in an early trial

Honey plus cryotherapy delayed and reduced radiation mouth sores in head and neck cancer patients

New ONS/ASCO guideline standardizes antidotes, compresses, and referral for chemo extravasation